Form 4: Aquestive Therapeutics SVP, Regulatory Affairs, Melina Cioffi, Reports Acquisition of 20,000 Shares of Common Stock

Melina Cioffi, SVP of Regulatory Affairs at Aquestive Therapeutics, reports acquiring 20,000 shares of common stock on May 15, 2025.

Summary

• Melina Cioffi, SVP of Regulatory Affairs at Aquestive Therapeutics, filed a Form 4 on May 15, 2025.
• The report indicates the acquisition of 20,000 shares of Aquestive Therapeutics common stock.
• The shares were acquired at a price of $0.
• Following the transaction, Cioffi beneficially owns 202,261 shares of common stock.
• The acquired common stock is represented by restricted stock vesting in three annual installments: 25% on the 1st, 25% on the 2nd, and 50% on the 3rd installment.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document is a standard regulatory filing detailing a stock transaction. The acquisition of shares by an executive is generally viewed as a positive signal, but the lack of specific context makes it difficult to assess the overall impact.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's performance.

Key Dates

Keywords

Aquestive Therapeutics, AQST, Melina Cioffi, Form 4, Beneficial Ownership, Stock Acquisition, Restricted Stock, SVP Regulatory Affairs